Share on

Europe Transfection Reagents And Equipment Market Research Report - Segmented By Product, Method, Application, End User & Country (UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic & Rest of Europe) - Industry Analysis, Size, Share, Growth, Trends, & Forecasts 2022 to 2027

Published: January, 2022
ID: 3088
Pages: 178

Europe Transfection Reagents and Equipment Market Size & Growth (2022 to 2027)

As per the research report, the Europe Transfection Reagents and Equipment market size is valued at USD 223.22 million in 2022. It is predicted to grow at a CAGR of 7.8 %, reaching USD 324.96 million by 2027 during the forecast period 2022 to 2027.

The increased frequency of infectious diseases, the usage of biopharmaceuticals in protein processing, and the rising obesity rate drive the expansion of transfection reagents and equipment in Europe.

The European transfection reagents and equipment market is driven by increased attention on protein therapies, government measures to boost health care, and the rising prevalence of cancer and cardiovascular diseases. The market is predicted to rise as advances in cell research, target validation, medication development, and technology developments, such as synthetic genes in high demand, are made. In addition, biosimilars are developed using a combination of genomes, proteomics, and cytological analyses, which necessitates the employment of a lot of transfection methods.

The transfection reagents and equipment market might be driven by increasing the adoption of reagents by the healthcare industry and research laboratories for future growth. In addition, the rising incidence of cancer diagnoses, established healthcare and pharmaceutical industry infrastructure, and expanding economies are all driving market expansion.

Increasing demand for synthetic genes is likely to create new opportunities for the Europe transfection reagents and equipment market during the forecast period. Furthermore, protein mass manufacturing is projected to propel the sector forward in the foreseeable future. Moreover, market participants might expect opportunities as large-scale transfections and developing markets grow.

The extraction of DNA and RNA by transfection reagents and equipment is costly, limiting the growth of the European transfection reagents and equipment market.

The scarcity of trained specialists at diagnostic centers may also harm the expansion rate. The ability to insert genetic material into a cell, the high cost of transfection reagents and supplies, the selective effectiveness of transfection reagents, and the procedure's cytotoxic consequences are expected to limit the market growth. The particular efficiency of transfection reagents and a ban on homebrew reagents being offered as consumer kits are anticipated to restrict demand for transfection reagents and devices.

This research report on the Europe Transfection Reagents and Equipment Market has been segmented and sub-segmented into the following categories.

By Product: 

  • Reagents
  • Instruments     

By Method:

  • Biochemical
  • Calcium Phosphate
  • Physical
  • Viral  

By Application:

  • Biomedical Research
  • Protein Production
  • Therapeutic Delivery           

By End User:

  • Academic & Research Institutes
  • Pharmaceutical & Biotechnology Companies  

By Country:

  • UK
  • France
  • Spain
  • Germany
  • Italy
  • Russia
  • Sweden
  • Denmark
  • Switzerland
  • Netherlands
  • Turkey
  • Czech Republic
  • Rest of Europe

Geographically, the Europe transfection reagents and equipment market is expected to use more biologically relevant but difficult to transfect cell models, as well as a broader range of nucleic acids, such as RNA variations, in addition to the typical immortalized cell lines, and these possibilities lead to unexpected turns that necessitate creativity over the projected period.

An increased focus on the production of protein therapies and agreements with prominent research institutes to stimulate drug discovery are driving the growth of the transfection reagents and equipment market in Europe. As a result, pharmaceutical and biotechnology businesses that can use transient transfection to produce high-yielding clinical and commercial batches of high-quality viral vectors may now provide this flexibility, scalability, and speed to market to their customers. In addition, academic research continues to push transfection technology forward. 

The German transfection reagents and equipment market is dominated in the European region due to rising demand for genomics and proteomics and increased government spending on health care in these countries.

The U.K transfection reagents and equipment market is estimated to hold the largest share of the European Transfection Reagents and Equipment market, followed by Germany. Rising cell science research and demand for chimeric genes and increased research and development investment and research efforts by pharmaceutical and biotech businesses are likely to create profitable prospects for the market.

KEY MARKET PLAYERS

Key players operating the Europe Transfection Reagents and Equipment Market profiled in this report are Thermo Fisher Scientific Inc., Promega Corporation, Hoffmann-La Roche Ltd. (Switzerland), QIAGEN N.V. (Netherlands), Bio-Rad Laboratories, Lonza Group (Switzerland), Sigma-Aldrich Corporation, Mirus Bio LLC and MaxCyte Inc.,

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 3335

Didn’t find what you’re looking for?
TALK TO OUR TEAM

Find it too expensive?
NO WORRIES!

Click for Request Sample